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Abstract. Inge Grundke-Iqbal and Khalid Iqbal found a connection between microtubule associated tau and Alzheimer’s disease.
They described that abnormally phosphorylated tau is a component of the paired helical filaments found in the disease. Afterwards
they described that tau hyperphosphorylation prevents microtubule assembly. Now trying to complement the relationship between
microtubules and tau phosphorylation, we have commented on the effect of microtubule disassembly on tau phosphorylation. In
this study, we investigated the role of microtubule depolymerization induced by nocodazole on tau phosphorylation in human
neuroblastoma SH-SY5Y cells. Our results indicate that nocodazole provokes tau phosphorylation mediated by GSK3, as
determined by using AT-8 or Tau-1 antibodies. Interestingly, total GSK3 and GSK3 phosphorylation on Ser-9 are not altered
during nocodazole treatment. In addition, microtubule stabilization with taxol had similar effects, likely because taxol and tau
compete for the same binding sites on microtubules, and in the presence of taxol, tau could be detached from microtubules. Thus,
unbound tau from microtubles can be phosphorylated by GSK3, even if the activity of GSK3 is not altered, probably because
tau unbound to microtubules could be a better substrate for the kinase than microtubule-associated tau. These findings suggest
that microtubule depolymerization can be a primary event in neurodegenerative disorders like Alzheimer’s disease and that tau
phosphorylation takes place afterwards.
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INTRODUCTION
Inge Grundke-Iqbal and Khalid Iqbal formed an
excellent team. Thanks to that team we know that
words like microtubules, tau, or phosphorylation
are related to Alzheimer’s disease (AD). In 1986,
Grundke-Iqbal et al. published two seminal works that
made wider the view of AD pathology, indicating that
tau protein was very important to understanding the
disease. Sometimes, to publish seminal papers is not
an easy task, and Inge and Khalid wrote in a review
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[1] how difficult it was to publish that microtubule-
associated tau was a component of paired helical
filaments. Two top journals rejected the paper that
finally was published in the Journal of Biological
Chemistry [2] and those top journals lost the 936 cita-
tions to that paper. Prior to publication, the manuscript
(in revision) was stolen, along with other things, from
their car and they started the writing work again [1].
Finally, the work was published, and some months
later they also published a second paper indicating that
tau present in paired helical filaments was abnormally
phosphorylated [3].
In this review, dedicated to Inge Grundke-Iqbal, we
will discuss the relationships between microtubules
(disassembly) and tau (phosphorylation).
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In AD, there are microtubule cytoskeleton changes
in the damaged neurons [4, 5]. A marker for these
changes is the microtubule-associated protein tau, in
phosphorylated form, a protein that is mainly modified
by GSK3 [6]. The consequences of those cytoskeletal
changes could be a net microtubule depolymeriza-
tion. Those microtubule changes could be induced
by presenilin-1 mutations [7] or by the increase in
amyloid- peptide levels [8] that could activate down-
stream a protein kinase like GSK3.
There are two hypotheses to link microtubule
depolymerization and tau phosphorylation. One of
these hypotheses suggests that tau phosphorylation
(based on the GSK3 over-activation) could be the first
event [9, 10]. Phospho-tau is unable to bind to micro-
tubules that lose their stability and could depolymerize.
The hypothesis is that such a process could take place
in AD. Indeed, it has been reported that tau hyperphos-
phorylation results in the disassembly of microtubules
[11, 12].
The other hypothesis suggests that microtubule
depolymerization is the first step [13] and that the
resulting free tau (unbound to microtubules) is a more
suitable substrate to be phosphorylated by GSK3 (or
other protein kinases) than tau bound to microtubules.
By looking at microtubule network reduction in sam-
ples from different stages of AD, it was determined that
microtubule depolymerization is probably the earliest
event and that tau phosphorylation occurs afterwards
[13].
In this work, we have tested that hypothesis in a
human neuroblastoma cell model. Our results indicate
that microtubule depolymerization is sufficient for the
promotion of tau phosphorylation without an increase
in GSK3 activity. It suggests that the increase in tau
phosphorylation is due to an increase in the amount
of an available and suitable substrate and not due to
a previous increase in kinase activity that could favor
phosphorylation of tau and its detachment from micro-
tubules.
METHODS
Reagents and antibodies
Nocodazole, paclitaxel (taxol), and AR-A014418
were purchased from Sigma. For immunoblot analy-
sis, the following anti-tau antibodies were used: 7.51
(1/1000; a kind gift from Dr. C. Wischik, University
of Aberdeen), AT-8 (1/200; Innogenetics, Ghent, Bel-
gium,) and tau-1 (1/2000; Chemicon, Temecula, CA).
Antibody AT-8 recognizes tau when serine 202 is phos-
phorylated [14], whereas antibody tau-1 recognizes tau
when it is dephosphorylated at serines 198, 199, and
202, and the 7.51 antibody recognizes total tau protein.
The numbering of the tau epitopes is given according
to the longest human tau isoform of 441 amino acids.
The other antibodies used were anti-phospho-GSK3
(Ser-9) and anti-GSK3 from Cell Signaling (1/1000,
Beverly, MA). The relevant secondary antibodies were
used (1/2000; DAKO).
For immunofluorescence, we used anti--tubulin
(1/500; Sigma), and the secondary antibody (Molecu-
lar Probes) was used at 1/1000. Biochemical reagents
were from Sigma, unless otherwise indicated. All other
chemicals were of analytical grade.
Culture of SH-SY5Y neuroblastoma cells
Human neuroblastoma SH-SY5Y cells were grown
in Dulbecco’s modified Eagle’s medium (Invitrogen-
Gibco, Carlsbad, CA) supplemented with 10% fetal
bovine serum (Invitrogen-Gibco), 2 mM glutamine,
and 50g/ml gentamycin. On the day before the exper-
iment, the cells were plated in multiwell plates with
neurobasal serum-free medium (Invitrogen-Gibco).
Data was presented as mean values ± SEM, of two or
three different experiments.
Immunoﬂuorescence analysis
For immunofluorescence studies, SH-SY5Y cells
were plated on glass cover slips coated with 1 mg/ml
polyL-lysine. After treatments, SH-SY5Y cells were
fixed with cooled methanol (−20◦C) for 20 min at 4◦C
and then washed with buffer A (0.1 M MES; 2 mM
EGTA; 0.5 mM MgCl2). Fixed cells were incubated
with 1 M glycine for 30 min and then permeabilized
with 0.2% Triton X-100 in buffer A for 5 min at room
temperature. The cover slips were blocked with 1%
BSA/ Buffer A for 1 h at room temperature and incu-
bated with primary antibodies in 1% BSA, in buffer A,
for 1 h at room temperature. After washing three times
with buffer A, the secondary antibody was incubated
for 1 h, at room temperature. Finally, the coverslips
were washed three times with PBS or with buffer A and
once with H2O, and mounted with FluorSave Reagent
(Calbiochem, San Diego, CA).
Gel electrophoresis and western blots
Cells were homogenized at 4◦C in 50 mM HEPES,
pH 7.4, 10 mM EDTA, 0.1% Triton X-100, includ-
ing the phosphatase inhibitors 20 mM NaF, 0.1 mM
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sodium orthovanadate, and with the following protease
inhibitors: 1 mM phenylmethanesulfonyl fluoride,
10g/ml pepstatin, and 10g/ml aprotinin. The cell
lysates were centrifuged at 10,000 g for 30 min at
4◦C and then heated at 100ºC for 5 min in elec-
trophoresis sample buffer. The protein concentration
was determined by using the BCA protein assay
(Pierce, Rockford, IL). Proteins were fractionated
by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) on 10% gels and transferred
to nitrocellulose membranes (Schleicher & Schuell
Bioscience, Dassel, Germany). After blocking of non-
specific protein binding to the membranes with 0.05%
Tween 20 and 5% nonfat dry milk in PBS, the mem-
branes were incubated overnight with the primary
antibodies in blocking buffer at 4ºC. The proteins rec-
ognized by the antibodies were visualized by using
enhanced chemiluminiscence (Perkin Elmer Life Sci-
ences, Boston, MA) after incubation with horseradish
peroxidase (HRP)-linked secondary antibodies (Dako
A/S, Glostrup, Denmark). Densitometric analysis of
labelled protein bands was performed with GS-710
software (Bio-Rad, Hercules, CA).
RESULTS
Nocodazole treatment results in microtubule
depolymerization and tau phosphorylation, in a
GSK3 dependent manner, in human
neuroblastoma cells
Nocodazole is a potent microtubule polymerization
inhibitor [15] and we have used this compound to
induce the disruption of microtubule network in a cul-
ture of human neuroblastoma cells. Figure 1 shows
an increase in tau phosphorylation at the residues
Fig. 1. Nocodazole treatment results in an increase of tau phosphorylation at the sites recognized by abTau-1 or abAT8. A) Representative
immunoblots of SH-SY5Y cells pretreated with vehicle, AR-A014418 (AR-18, 33M) or lithium (20 mM) for 1 h and then with nocodazole
(10M) for 0, 5, or 15 min. The samples were immunoblotted with the Tau-1 antibody. B) Quantified data of Tau-1 levels are expressed in
terms of the percentage of the signal present at before nocodazole adding ( - vehicle,  - AR18,  - Lithium). C) Reaction of tau with abAT8
(a) (that recognizes phospho tau) in the absence (−) or presence (+) of 10M nocadazole, after 15 min of treatment. At the left, bottom of the
figure (b), the reaction with an antibody against GAPDH used as protein loading marker or (c) with ab7.51, a tau antibody that recognizes the
protein independently of its phosphorylation status is shown. Quantified data are expressed in terms of arbitrary units (AU) of optical density
(OD). The electrophoretic mobility of a protein marker (MW) is also shown.
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Fig. 2. Effect of nocodazole on microtubule network of SH-SY5Y cells. A) Nocodazole (10M) treated SH-SY5Y cells (+) were washed
to remove the drug and tau phosphorylation was measured (using tau-1 antibody) 15 min after nocodazole removal (–). SH-SY5Y human
neuroblastoma cells were cultured, fixed, and stained with tubulin antibody in the absence B) or presence of nocodazole C) for 15 min. D)
After incubation, nocodazole was removed and, after 15 min, the cultured cells were fixed and stained with tubulin antibody to test microtubule
network recovery. Quantified data are expressed in terms of arbitrary units (AU) of optical density (OD). The electrophoretic mobility of protein
markers (MW) are also shown.
196-202 in the presence of nocodazole. This analysis
was carried out by using two complementary antibod-
ies, Tau-1 (Fig. 1A-B, that reacts with those residues
only if they are in dephosphorylated form) and with
its complementary antibody, AT8 (Fig. 1C), that only
reacts if the residue 202 is phosphorylated. As shown
in Fig. 1, upon addition of nocodazole an increase in
the reaction with AT8 and a decrease in the reaction
with Tau-1 was found.
To test if GSK3 is indeed the kinase involved in
the phosphorylation recognized by Tau-1 antibody, as
previously suggested [16, 17], we have added two
inhibitors of GSK3 (lithium and AR-A014418) in
the presence of nocodazole treatment. Figure 1A, B
shows that in the presence of both GSK3 inhibitors the
increase in tau phosphorylation, induced by nocoda-
zole, was prevented, suggesting that GSK-3 was the
kinase involved in the phosphorylation of that site on
tau molecule. As indicated by other groups [18] we
cannot rule out that other kinases may also modify tau
at the AT8 site. However, it has also been shown that
under certain conditions, tau is mainly phosphorylated
at that site by GSK3 [18], a result that agrees well with
the data shown in Fig. 1.
Taking into account that nocodazole is a reversible
microtubule polymerization inhibitor [15], we have
analyzed if these effects on tau phosphorylation revert
after removing the compound. Figure 2A shows a
decrease in tau phosphorylation at Tau-1 epitope
(an increase in antibody labeling) after removing
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Fig. 3. There is no increase in active GSK3 upon microtubule depolymerization. SH-SY5Y cultured cells were incubated in the absence or
presence of 10M nocodazole (0, 5, 15, 30 min) and the levels of A) phosphorylated (at serine 9) GSK3, and B) total GSK3, were measured
by using specific antibodies. C) Quantified data of GSK3 () and p-GSK3 () levels are expressed in terms of arbitrary units (AU) of optical
density (OD). The electrophoretic mobility of a protein marker (MW) is also shown.
nocadazole from the culture. To analyze the effect
of these treatments on microtubule network, we per-
formed immunofluorescence analysis of SH-SY5Y
cells with an anti-tubulin antibody. Figure 2B-D shows
the presence of the microtubule lattice in neuroblas-
toma cells in the absence of nocodazole (Fig. 2B);
while in the presence of nocodazole (panel 2C), a loss
of the network was found. Microtubule assembly was
recovery after removing the nocodazole from the cul-
ture (Fig. 2D).
There is no increase in GSK3 activity upon
microtubule depolymerization
A routinely used method to test for GSK3 activ-
ity is to identify levels of phosphorylation at serine 9.
Figure 3 shows that upon addition of nocodazol, dif-
ferences in the level of GSK3 phosphorylation were
not found. This result suggests that the increase in tau
phosphorylation by GSK3 is not due to an increase
in the kinase activity.
Taxol treatment results in microtubule stabilization
and tau phosphorylation in human neuroblastoma
cells
Taxol binds to-tubulin and stabilizes microtubules.
Interestingly, taxol could bind to a site on microtubules
where tau also binds [19]. We have used this compound
to stabilize microtubules (Fig. 4C-D) and to analyze its
effects on tau phosphorylation, since in the presence
of taxol, the amount of tau unbound to microtubules
increases. Figure 4A-B shows an increase in tau phos-
phorylation at the residues 196-202 in the presence of
taxol as it is demonstrated by the increase observed
with the AT-8 antibody and the decrease obtained with
the Tau-1 antibody.
DISCUSSION
Our results support the possibility that microtubule
depolymerization (in our case induced with nocoda-
zole) could be an early event inducing a subsequent tau
phosphorylation similar to that found in neurodegen-
erative disorders like AD. It agrees with the previous
observations done on human samples [13] and with
a recent study suggesting that rotenone (that could
act like an inhibitor of microtubule polymerization
[20]) facilitates tau phosphorylation [21]. Interestingly,
stathmin, a microtubule-disrupting protein, has similar
effects [22]. In good agreement with these data, taxol
also induces an increase in tau phosphorylation. Tau
binding to microtubules is sensitive to taxol [19] and
we have observed an increase in tau phosphorylation
probably because tau competes with taxol provoking
an increase in unbound tau. This unbound tau is likely
a suitable substrate for phosphorylation.
Recently, NAP (davunetide), a peptide that pro-
tects microtubules from nocodazol depolymerization
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Fig. 4. Taxol treatment results in an increase of tau phosphorylation at the sites recognized by AT8 or Tau-1 antibodies. A) Representative
immunoblots of SH-SY5Y cells pretreated with DMSO or taxol (10M) for 15 min. The samples were immunoblotted with the AT-8, Tau-1,
or 7.51 antibodies; ab7.51 is an antibody that reacts with total tau. B) Quantitation of the data shown in (A) for AT8 (left) and for Tau-1 (right)
antibodies. C, D) SH-SY5Y human neuroblastoma cells were cultured, fixed, and stained with tubulin antibody to test microtubule network in
the absence (C) or presence (D) of taxol (10M) for 15 min.
[23], and unlike taxol, was found to enlist tau to the
microtubule network [24], preventing tau hyperphos-
phorylation [25]. This strengthens the current data
indicating that microtubule breakdown precedes tau
hyperphosphorylation.
Our results demonstrate that tau phosphorylation
is reversible since removing nocodazole from culture
induces microtubule repolymerization as well as tau
dephosphorylation (Fig. 2).
Although factors like amyloid- peptide could
facilitate the increase in GSK3 activity through dif-
ferent pathways [26–28], our results indicate that such
activation is not necessary for an increase in tau phos-
phorylation (Fig. 3). We suggest that upon microtubule
depolymerization, tau that is not bound to microtubules
is available for modification by the kinase and that it
could be the way to explain the increase in tau phospho-
rylation observed in some neurodegenerative diseases.
Our results emphasize the importance of micro-
tubule dynamics on tau phosphorylation suggesting
that microtubule depolymerization can be a primary
event in neurodegenerative disorders like AD.
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